跳至主要内容
临床试验/NCT06119347
NCT06119347已完成不适用

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study

First Affiliated Hospital of Wenzhou Medical University1 个研究点 分布在 1 个国家目标入组 1,581 人开始时间: 2020年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,581
试验地点
1
主要终点
accumulative incidence of sustained AKI

研究概览

简要总结

The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs). The main question it aims to answer is whether the choice between AntiVEGF and ICIs affects the risks of acute kidney injury in cancer patients.

Cancer patients receiving AntiVEGF will be compared to those treated with ICIs to see if the AKI incidence is higher in patients receiving ICIs.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >=20yr;
  • Patients must have at least one "Evaluation and Management"visit with a diagnosis of cancer within 12 months before index date (In situ biopsy will not be required, since patients may receive a diagnosis from a biopsy of metastatic site);
  • Indication to initiate AntiVEGF or ICIs

排除标准

  • Patients without valid data and less than 3 months followup;
  • Patients without baseline Scr value within 12 mon before index date;
  • Patients with combination therapy of Anti-VEGF and ICIs ;
  • Patients with chronic renal failure

研究组 & 干预措施

AntiVEGF

cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF)

干预措施: AntiVEGF (Drug)

ICIs

cancer patients receiving immune checkpoint inhibitors (ICIs).

干预措施: ICIs (Drug)

结局指标

主要结局

accumulative incidence of sustained AKI

时间窗: 12 months after index date

sustained AKI will be defined as the elevation ≥1.5 times baseline sCr for ≥72hours according to the Kidney Disease Improving Global Outcomes (KDIGO) sCr criteria

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tianxin Chen

Principal Investigator

First Affiliated Hospital of Wenzhou Medical University

研究点 (1)

Loading locations...

相似试验